The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
A Novel Antiinflammatory Maintains Glucocorticoid Efficacy with Reduced Side Effects
Abstract
Glucocorticoids (GCs) are commonly used to treat inflammatory disease; unfortunately, the long-term use of these steroids leads to a large number of debilitating side effects. The antiinflammatory effects of GCs are a result of GC receptor (GR)-mediated inhibition of expression of proinflammatory genes as well as GR-mediated activation of antiinflammatory genes. Similarly, side effects are most likely due to both activated and repressed GR target genes in affected tissues. An as yet unachieved pharmaceutical goal is the development of a compound capable of separating detrimental side effects from antiinflammatory activity. We describe the discovery and characterization of AL-438, a GR ligand that exhibits an altered gene regulation profile, able to repress and activate only a subset of the genes normally regulated by GCs. When tested in vivo, AL-438 retains full antiinflammatory efficacy and potency comparable to steroids but its negative effects on bone metabolism and glucose control are reduced at equivalently antiinflammatory doses. The mechanism underlying this selective in vitro and in vivo activity may be the result of differential cofactor recruitment in response to ligand. AL-438 reduces the interaction between GR and peroxisomal proliferator-activated receptor γ coactivator-1, a cofactor critical for steroid-mediated glucose up-regulation, while maintaining normal interactions with GR-interacting protein 1. This compound serves as a prototype for a unique, nonsteroidal alternative to conventional GCs in treating inflammatory disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1
Yoon, J. C., Puigserver, P., Chen, G., Donovan, J., Wu, Z., Rhee, J., Adelmant, G., Stafford, J., Kahn, C. R., Granner, D. K., et al. (2001) · Nature · doi:10.1038/35093050 · Cited by 1,821 · cited 11×
“GC regulation of hepatic glucose production has recently been connected directly to the transcriptional coactivator PGC-1 (16, 17), and GRIP-1 appears to play a role in transcriptional repression by GR of proinflammatory genes (19).”
BackgroundInfluentialAnti-inflammatory Actions of Glucocorticoids: Molecular Mechanisms
Barnes, P. J. (1998) · Clinical Science · doi:10.1042/cs0940557 · Cited by 1,591
Stress Hormones, Proinflammatory and Antiinflammatory Cytokines, and Autoimmunity
ELENKOV, I. J., & CHROUSOS, G. P. (2002) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2002.tb04229.x · Cited by 983
Hofbauer, L. C., Gori, F., Riggs, B. L., Lacey, D. L., Dunstan, C. R., Spelsberg, T. C., & Khosla, S. (1999) · Endocrinology · doi:10.1210/endo.140.10.7034 · Cited by 794
Nissen, R. M., & Yamamoto, K. R. (2000) · Genes & Development · doi:10.1101/gad.827900 · Cited by 559
Novel glucocorticoid receptor coactivator effector mechanisms
Jenkins, B. D., Pullen, C. B., & Darimont, B. D. (2001) · Trends in Endocrinology & Metabolism · doi:10.1016/s1043-2760(00)00357-x · Cited by 150
Cited by
Metabolic control through the PGC-1 family of transcription coactivators
Lin, J., Handschin, C., & Spiegelman, B. M. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.05.004 · Cited by 2,130
“In fact, it has been demonstrated as a proof of principle that agonist ligands for the GR can be developed that promote docking of the coactivator GRIP1 to the GR while not promoting PGC-1α docking; these compounds have reduced hyperglycemic activity (Coghlan et al., 2003).”
BackgroundPrinciples for modulation of the nuclear receptor superfamily
Gronemeyer, H., Gustafsson, J.-Å., & Laudet, V. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1551 · Cited by 1,226
Coregulator Function: A Key to Understanding Tissue Specificity of Selective Receptor Modulators
Smith, C. L., & O’Malley, B. W. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0023 · Cited by 931
De Bosscher, K., Vanden Berghe, W., & Haegeman, G. (2003) · Endocrine Reviews · doi:10.1210/er.2002-0006 · Cited by 898
A General Introduction to Glucocorticoid Biology
Timmermans, S., Souffriau, J., & Libert, C. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01545 · Cited by 609
Schäcke, H., Schottelius, A., Döcke, W.-D., Strehlke, P., Jaroch, S., Schmees, N., Rehwinkel, H., Hennekes, H., & Asadullah, K. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0300372101 · Cited by 466
Ratman, D., Vanden Berghe, W., Dejager, L., Libert, C., Tavernier, J., Beck, I. M., & De Bosscher, K. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2012.12.014 · Cited by 411
Biological control through regulated transcriptional coactivators
Spiegelman, B. M., & Heinrich, R. (2004) · Cell · doi:10.1016/j.cell.2004.09.037 · Cited by 377
Newton, R., & Holden, N. S. (2007) · Molecular Pharmacology · doi:10.1124/mol.107.038794 · Cited by 328
Beck, I. M. E., Vanden Berghe, W., Vermeulen, L., Yamamoto, K. R., Haegeman, G., & De Bosscher, K. (2009) · Endocrine Reviews · doi:10.1210/er.2009-0013 · Cited by 298
Minireview: Latest Perspectives on Antiinflammatory Actions of Glucocorticoids
De Bosscher, K., & Haegeman, G. (2009) · Molecular Endocrinology · doi:10.1210/me.2008-0283 · Cited by 284
Nuclear Receptors and Their Selective Pharmacologic Modulators
Burris, T. P., Solt, L. A., Wang, Y., Crumbley, C., Banerjee, S., Griffett, K., Lundasen, T., Hughes, T., & Kojetin, D. J. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.006833 · Cited by 283
Crosstalk between the glucocorticoid receptor and other transcription factors: Molecular aspects
Kassel, O., & Herrlich, P. (2007) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2007.07.003 · Cited by 277
A fully dissociated compound of plant origin for inflammatory gene repression
De Bosscher, K., Berghe, W. V., Beck, I. M. E., Van Molle, W., Hennuyer, N., Hapgood, J., Libert, C., Staels, B., Louw, A., & Haegeman, G. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0505554102 · Cited by 260
Kleiman, A., & Tuckermann, J. P. (2007) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2007.05.009 · Cited by 165
“…elevation decreased, spleen involution decreased, skin atrophy slightly decreased, adrenocorticotropic hormone suppression not changed AL-438 (Coghlan et al., 2003) carageenan-induced arthritis, adjuvant induced arthritis efficiently reduced hyperglycemia decreased, inhibition of bone…”
BackgroundWong, S. C., Dobie, R., Altowati, M. A., Werther, G. A., Farquharson, C., & Ahmed, S. F. (2016) · Endocrine Reviews · doi:10.1210/er.2015-1026 · Cited by 163
The GRIP1:IRF3 interaction as a target for glucocorticoid receptor-mediated immunosuppression
Reily, M. M., Pantoja, C., Hu, X., Chinenov, Y., & Rogatsky, I. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7600919 · Cited by 149
Effects of dissociated glucocorticoids on OPG and RANKL in osteoblastic cells.
Humphrey, E. L., Williams, J. H. H., Davie, M. W. J., & Marshall, M. J. (2006) · Bone · doi:10.1016/j.bone.2005.10.004 · Cited by 139
Chinenov, Y., & Rogatsky, I. (2007) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2007.04.014 · Cited by 133
Schäcke, H., Zollner, T., Döcke, W., Rehwinkel, H., Jaroch, S., Skuballa, W., Neuhaus, R., May, E., Zügel, U., & Asadullah, K. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00238.x · Cited by 121
Ronacher, K., Hadley, K., Avenant, C., Stubsrud, E., Simons, S. S., Louw, A., & Hapgood, J. P. (2009) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2008.10.008 · Cited by 121
Differential targeting of brain stress circuits with a selective glucocorticoid receptor modulator
Zalachoras, I., Houtman, R., Atucha, E., Devos, R., Tijssen, A. M. I., Hu, P., Lockey, P. M., Datson, N. A., Belanoff, J. K., Lucassen, P. J., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1219411110 · Cited by 121
The biology of PGC-1α and its therapeutic potential
Handschin, C. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.03.006 · Cited by 108
Central role of glucocorticoid receptors in Alzheimer's disease and depression
Canet, G., Chevallier, N., Zussy, C., Desrumaux, C., & Givalois, L. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00739 · Cited by 106
Metadata
- Authors
- Coghlan, M. J., Jacobson, P. B., Lane, B., Nakane, M., Lin, C. W., Elmore, S. W., Kym, P. R., Luly, J. R., Carter, G. W., Turner, R., Tyree, C. M., Hu, J., Elgort, M., Rosen, J., & Miner, J. N.
- Venue
- Molecular Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2003-05-01
- Volume
- 17
- Issue
- 5
- Pages
- 860-869
- ISSN
- 0888-8809 (ISSN-L)
- 1944-9917
- OpenAlex
- W2095060581
- Cited by
- 224
- References
- 6
- FWCI
- 8.71
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.